Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects

Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. Although the detailed molecular mechanism of acamprosate remains unclear, it has been largely known that acamprosate inhibits glutamate action in the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Psychiatry
Main Authors: Nam, H W, Karpyak, V M, Hinton, D J, Geske, J R, Ho, A M C, Prieto, M L, Biernacka, J M, Frye, M A, Weinshilboum, R M, Choi, D-S
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4564571/
https://ncbi.nlm.nih.gov/pubmed/26285131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tp.2015.120
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados